CTLA4 and cancer: METTL1 may be effective in the treatment of HNSC and other cancers through the targeting of other immune checkpoints, including the T-cell Ig and ITIM structural domains (TIGIT), or the cytotoxic T lymphocyte-associated protein 4 (CTLA-4).